Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGT Releases New CytoSure™ Microarray

Published: Tuesday, March 26, 2013
Last Updated: Tuesday, March 26, 2013
Bookmark and Share
Simultaneous detection of CNVs, SNPs and LOH on a single array using any reference sample.

Oxford Gene Technology (OGT) has released a new microarray to improve the accuracy and efficiency of cancer research.

The CytoSure™ Cancer +SNP array (4x180k) combines long oligo array comparative genomic hybridization (aCGH) probes with fully validated single nucleotide polymorphism (SNP) content, providing the superior detection of both copy number variations (CNVs) and loss of heterozygosity (LOH) on a single chip.

The array has been optimized in collaboration with Professor Jacqueline Schoumans from the Lausanne University Hospital in Switzerland, an expert in both aCGH and cancer genomics.

Unique to the proprietary CytoSure™ Cancer +SNP array, any reference sample can be used for analysis without changes to the standard aCGH protocol and, thanks to novel SNP probe chemistry, no restriction digest is required.

The capacity to use matched samples is a particular advantage for research into genetic aberrations in cancer, enabling any constitutional abnormalities to be filtered out.

Professor Schoumans commented: “The development of a new microarray with the capacity to detect both CNVs and LOH simultaneously was vital for improving the efficiency and quality of our research. By working very closely with the technical experts at OGT, we have constructed a new array that allows users to simultaneously screen a wide genomic background for CNVs and LOH, while also enabling in-depth CNV analysis on 1500 known cancer-associated genes. This approach produces accurate and insightful data, with all aberrations clearly highlighted and filtered using OGT’s excellent CytoSure Interpret Software.”

The 60-mer oligonucleotide probes utilized in the array provide a high signal-to-noise ratio and highly sensitive detection; this makes them ideal for research into complex malignant tissues.

Thanks to OGT’s CytoSure Interpret Software, data analysis is rapid, reliable and simple to carry out, including updated features, such as the B-allele frequency plot, that have been optimized for the identification of biologically relevant genomic variants in tumour samples.

James Clough, Executive Vice President Commercial at OGT, said: “The new CytoSure™ Cancer +SNP array forms part of OGT’s ongoing strategy to design specialized microarrays to help increase our understanding of cancer formation and development. We plan to further add to this portfolio in the coming months, with the introduction of our Cancer Cytogenomics Microarray Consortium (CCMC) array design. By offering both genome-wide CNV and SNP detection, these arrays will prove a valuable tool for efficiently and accurately defining the genetic nature of a given tumour, facilitating research into more efficacious, targeted treatments.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oxford Gene Technology Expands Leadership in Genomic Medicine
The Company today announced the acquisition of Cambridge-based Cytocell Limited.
Tuesday, March 04, 2014
OGT Strengthens Focus on Cancer Biomarkers
Oxford Gene Technology announce the appointment of Dr Bob Holland as Chief Medical Officer.
Monday, October 21, 2013
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Awarded Best Medtech Dealmaker by Oxford Bioscience Network
Award recognizes OGT’s collaboration with Birmingham and Salisbury NHS Regional Genetics Laboratories.
Wednesday, October 09, 2013
Exploring the Next Generation of Cancer Genomics at BSGM
aCGH to NGS: OGT invites University of Oxford Professor to present latest research.
Thursday, September 12, 2013
OGT Forms Scientific Advisory Board
Peter Rigby appointed as SAB Chairman.
Wednesday, September 12, 2012
Oversubscribed OGT Workshop at ESHG 2012 Now Available Online
Experts discuss the use of arrays and NGS to identify causative mutations in cancer.
Thursday, July 19, 2012
OGT Signs Licensing Deal for Colorectal Cancer Biomarkers
OGT has entered into an exclusive licensing agreement with Inven2.
Thursday, February 23, 2012
Oxford Gene Technology and Abcodia Form Partnership
Companies combine expertise to advance biomarkers for the early diagnosis of pancreatic cancer.
Tuesday, November 08, 2011
OGT’s miRNA Profiling Service Provides Answers for Disease Research
Company has designed the microRNA profiling service designed to help researchers accelerate their discoveries.
Friday, May 16, 2008
Scientific News
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Biomarkers That Could Help Give Cancer Patients Better Survival Estimates Discovered
UCLA research may also help scientists suppress dangerous genetic sequences.
Body’s Own Gene Editing System Generates Leukemia Stem Cells
Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!